Profound Medical Corp. (PROF)
Profound Medical Corp. (PROF) Stock Price, Analysis & Data
| Bid | 4.99 |
| Market Cap | 251.82M |
| Revenue (ttm) | 19.09M |
| Net Income (ttm) | -32.74M |
| Beta | 0.53 |
| EPS (ttm) | -0.99 |
| PE Ratio (ttm) | n/a |
| Forward PE | -11.79 |
| P/B (ttm) | 4.24 |
| P/S (ttm) | 13.19 |
| Earnings Date | Nov 12, 2026 |
| Ask | 8.78 |
| Volume | 116,748 |
| Avg. Volume (20D) | 84,324 |
| Open | 7.04 |
| Previous Close | 6.98 |
| Day's Range | 6.80 - 7.04 |
| 52-Week Range | 3.76 - 8.95 |
| Analyst | Strong Buy |
| Price Target | 11.2 (61.62%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PROF
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defi...
Financial Performance
In 2025, Profound Medical's revenue was 16.1M, an increase of 50.73% compared to the previous year's 10.68M. Earnings were -42.57M, an increase of 53.04%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for PROF stock is "Strong Buy". The 12-month stock price forecast is 11.2, which is upside of 61.62% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
